B type natriuretic peptide testing: Where are we now?

Heart

Volumn 90, Issue 7, 2004, Pages 725-726

  Cowie, M R ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

BIOASSAY; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE MARKER; EDITORIAL; HEART FAILURE; HEART VENTRICLE FAILURE; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK ASSESSMENT;

EID: 3042638626     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2003.014787     Document Type: Editorial

References (18)

1. Cowie MR, Jourdain P, Maisel A, et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003;24:1710-8.
2. Cowie MR, Mendez GF. BNP and congestive heart failure. Prog CV Disease 2002;44:293-321.
3. Dao Q, Khrishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-85.
4. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349-51.
5. Maisel AS, McCord J, Nowak RM, et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the breathing not properly multinational study. J Am Coll Cardiol 2003;41:2010-7.
6. Zaphiriou A, Robb S, Murray-Thomas T, et al. Ruling out heart failure with BNP or NTproBNP: does it work in practice? Results of the UK natriuretic peptide study [abstract]. Heart 2003;89(suppl I):A49.
7. The Task Force for ths Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart Failure. Eur Heart J 2001;22:1527-60.
8. National Institute for Clinical Excellence. Chronic heart failure: management of chronic heart failure in adults in primary and secondary care. London: NICE, 2003.
9. Wright SP, Doughty RN, Pearl A, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 2003;42:1793-800.
10. Hobbs FD, Davis RC, Roalfe AK, et al. Reliability of N-terminal probrain natriuretic peptide in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 2002;324:1498-502.
11. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002;288:1252-9.
12. McDonagh T, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
13. Smith H, Pickering RM, Struthers AD, et al. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study. BMJ 2000;320:906-8.
14. Gardner RS, Ozalp F, Murday AJ, et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003;24:1735-43.
15. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type natriuretic peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 200;37:386-91.
16. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
17. Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002;106:2913-8.
18. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.